细胞毒性
肿瘤微环境
癌细胞
体内
癌症研究
外渗
癌症
癌症免疫疗法
免疫系统
免疫学
离体
细胞毒性T细胞
细胞
免疫疗法
医学
血管生成
流式细胞术
生物
体外
炎症
内科学
生物化学
遗传学
作者
Jiyoung Song,Hyeri Choi,Seung Kwon Koh,Noo Li Jeon,James Yu,Habin Kang,Young-Taek Kim,Duck Cho,Noo Li Jeon
标识
DOI:10.3389/fimmu.2021.733317
摘要
Recent advances in anticancer therapy have shown dramatic improvements in clinical outcomes, and adoptive cell therapy has emerged as a type of immunotherapy that can modulate immune responses by transferring engineered immune cells. However, a small percentage of responders and their toxicity remain as challenges. Three-dimensional (3D) in vitro models of the tumor microenvironment (TME) have the potential to provide a platform for assessing and predicting responses to therapy. This paper describes an in vitro 3D tumor model that incorporates clusters of colorectal cancer (CRC) cells around perfusable vascular networks to validate immune-cell-mediated cytotoxicity against cancer cells. The platform is based on an injection-molded 3D co-culture model and composed of 28 microwells where separate identical vascularized cancer models can be formed. It allows robust hydrogel patterning for 3D culture that enables high-throughput experimentation. The uniformity of the devices resulted in reproducible experiments that allowed 10× more experiments to be performed when compared to conventional polydimethylsiloxane (PDMS)-based microfluidic devices. To demonstrate its capability, primary natural killer (NK) cells were introduced into the vascularized tumor network, and their activities were monitored using live-cell imaging. Extravasation, migration, and cytotoxic activity against six types of CRC cell lines were tested and compared. The consensus molecular subtypes (CMS) of CRC with distinct immune responses resulted in the highest NK cell cytotoxicity against CMS1 cancer cells. These results show the potential of our vascularized tumor model for understanding various steps involved in the immune response for the assessment of adoptive cell therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI